Similar Search Results

Western European Markets for biosimilar and generic drugs : worth differentiating : Editorial

Garattini, Livio; Curto, Alessandro; Van de Vooren, … - In: The European journal of health economics : HEPAC ; … 16 (2015) 7, pp. 683-687

Persistent link: https://www.econbiz.de/10011482938

Access to primary care in Italy : time for a shake-up?

Garattini, Livio; Curto, Alessandro; Freemantle, Nick - In: The European journal of health economics : HEPAC ; … 17 (2016) 2, pp. 113-116

Persistent link: https://www.econbiz.de/10011486395

Editorial: market approval for drugs in the EU : time to change direction?

Curto, Alessandro; Van de Vooren, Katelijne; Garattini, … - In: The European journal of health economics : HEPAC ; … 18 (2017) 8, pp. 933-936

Persistent link: https://www.econbiz.de/10011869154

Editorial: reimbursable drug classes and ceilings in Italy : why not only one?

Garattini, Livio; Curto, Alessandro; Padula, Anna - In: The European journal of health economics : HEPAC ; … 17 (2016) 8, pp. 923-926

Persistent link: https://www.econbiz.de/10011660068

Comment on: “Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers”

Curto, Alessandro; Garattini, Livio - In: Applied Health Economics and Health Policy 12 (2014) 5, pp. 565-565

Persistent link: https://www.econbiz.de/10011000736

The Authors' Reply

Garattini, Livio; van de Vooren, Katelijne; Curto, … - In: PharmacoEconomics 30 (2012) 5, pp. 443-445

Persistent link: https://www.econbiz.de/10010541094

Pricing Human Papillomavirus Vaccines: Lessons from Italy

Garattini, Livio; van de Vooren, Katelijne; Curto, … - In: PharmacoEconomics 30 (2012) 3, pp. 213-217

Persistent link: https://www.econbiz.de/10009493380

Regional HTA in Italy: Promising or confusing?

Garattini, Livio; van de Vooren, Katelijne; Curto, … - In: Health Policy 108 (2012) 2, pp. 203-206

We assessed the actual implementation and achievements of regional HTA in Italy.

Persistent link: https://www.econbiz.de/10010594653

Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU?

Garattini, Livio; van de Vooren, Katelijne; Curto, … - In: Health Policy 119 (2015) 2, pp. 212-216

Trastuzumab (TR), a monoclonal antibody approved by EMA in 2000 and one of the first examples of “targeted therapy”, is indicated to treat human epidermal growth factor receptor 2 (HER2) positive breast cancer. TR, whose patent will expire in 2015 in Europe, has been judged positively for...

Persistent link: https://www.econbiz.de/10011190167

Le système de santé publique italien

Garattini, Livio - 1993

Persistent link: https://www.econbiz.de/10004185471